Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EPS (Basic) (2024 - 2025)

Historic EPS (Basic) for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$0.26.

  • Prelude Therapeutics' EPS (Basic) rose 3953.49% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year change of. This contributed to the annual value of -$1.84 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' EPS (Basic) stood at -$0.26, which was up 3953.49% from -$0.45 recorded in Q4 2024.
  • In the past 5 years, Prelude Therapeutics' EPS (Basic) ranged from a high of -$0.26 in Q3 2025 and a low of -$0.45 during Q4 2024